Basic Principles of Intravenous Immunoglobulin (IVIg) Treatment

Overview

Journal J Neurol

Specialty Neurology

Date 2006 Sep 26

PMID 16998749

Citations 22

Authors

Martin Stangel

Refik Pul

Affiliations

Soon will be listed here.

Abstract

The original rationale for the therapeutic application of immunoglobulins was prevention and treatment of infectious diseases. With the description of agammaglobulinemia, substitution therapy became the primary indication for the use of immunoglobulins. Limitations and side effects of the intramuscular administration of immunoglobulins led to the development of preparations for intravenous use (IVIg). In the early 1980s an immunomodulatory effect of IVIg was described. Since then, the efficacy of IVIg has been established in controlled trials for diseases like idiopathic thrombocytopenic purpura, Kawasaki disease, Guillain-Barré syndrome, dermatomyositis, and many others. There is a large body of evidence that IVIg can modulate an immune reaction at the level of T cells, B cells, and macrophages, interferes with antibody production and degradation, modulates the complement cascade, and has effects on the cytokine network. However, the precise mechanism of action is not yet clear.

Citing Articles

Targeted Treatments for Myasthenia Gravis in Children and Adolescents.

Ramdas S, Painho T, Vanegas M, Famili D, Lim M, Jungbluth H Paediatr Drugs. 2024; 26(6):719-740.

PMID: 39198371 DOI: 10.1007/s40272-024-00649-3.

Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.

Gao Y, Jin H Ther Adv Chronic Dis. 2022; 13:20406223221097331.

PMID: 35634570 PMC: 9134453. DOI: 10.1177/20406223221097331.

High-dose IgG suppresses local inflammation and facilitates functional recovery after olfactory system injury.

Nishida K, Kobayashi M, Ishigami E, Takeuchi K Ann Clin Transl Neurol. 2022; 9(6):770-777.

PMID: 35588199 PMC: 9186131. DOI: 10.1002/acn3.51554.

Selective depletion of radiolabeled HER2-specific antibody for contrast improvement during PET.

Khare P, Sun W, Ramakrishnan S, Hao G, Lo S, Nham K MAbs. 2021; 13(1):1976705.

PMID: 34592895 PMC: 8489906. DOI: 10.1080/19420862.2021.1976705.

Application of 3D bioprinting in the prevention and the therapy for human diseases.

Yi H, Kim H, Kwon J, Choi Y, Jang J, Cho D Signal Transduct Target Ther. 2021; 6(1):177.

PMID: 33986257 PMC: 8119699. DOI: 10.1038/s41392-021-00566-8.

References

LUTHARDT T . [Intravenous immunoglobulin administration for antibody deficiency (author's transl)]. Dtsch Med Wochenschr. 1980; 105(28):993-7. DOI: 10.1055/s-2008-1070798. View

Samuelsson A, Towers T, Ravetch J . Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001; 291(5503):484-6. DOI: 10.1126/science.291.5503.484. View

Lapointe B, Herx L, Gill V, Metz L, Kubes P . IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain. 2004; 127(Pt 12):2649-56. DOI: 10.1093/brain/awh297. View

Heiken H, Schmidt R . [Indications for the use of immunoglobulin therapy]. Dtsch Med Wochenschr. 2003; 128(31-32):1665-9. DOI: 10.1055/s-2003-41098. View

Hurez V, Kaveri S, Mouhoub A, Dietrich G, Mani J, Klatzmann D . Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol. 1994; 1(5):269-77. View

Kleyweg R, van der Meche F, Meulstee J . Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology. 1988; 38(10):1639-41. DOI: 10.1212/wnl.38.10.1639. View

Nolte M, PIROFSKY B, Gerritz G, Golding B . Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol. 1979; 36(2):237-43. PMC: 1537711. View

Aukrust P, Froland S, Liabakk N, Muller F, Nordoy I, Haug C . Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994; 84(7):2136-43. View

Bouhlal H, Hocini H, Donkova V, Rose S, Amara A, Longhi R . Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol. 2001; 166(12):7606-11. DOI: 10.4049/jimmunol.166.12.7606. View

10.

MATTHEWS D, Matthews J, Aynsley-Green A, Bullock R, Eyre J . Changes in cerebral oxygen consumption are independent of changes in body oxygen consumption after severe head injury in childhood. J Neurol Neurosurg Psychiatry. 1995; 59(4):359-67. PMC: 486069. DOI: 10.1136/jnnp.59.4.359. View

11.

Prasad N, Papoff G, Zeuner A, Bonnin E, Kazatchkine M, Ruberti G . Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998; 161(7):3781-90. View

12.

Vassilev T, Kazatchkine M, Duong van Huyen J, Mekrache M, Bonnin E, Mani J . Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood. 1999; 93(11):3624-31. View

13.

Frank M, Basta M, Fries L . The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol. 1992; 62(1 Pt 2):S82-6. DOI: 10.1016/0090-1229(92)90045-p. View

14.

Gajdos P, Outin H, Elkharrat D, Brunel D, Raphael J, GOULON M . High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984; 1(8373):406-7. DOI: 10.1016/s0140-6736(84)90469-0. View

15.

Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D . Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998; 282(5388):490-3. DOI: 10.1126/science.282.5388.490. View

16.

Stephan W . Undegraded human immunoglobulin for intravenous use. Vox Sang. 1975; 28(6):422-37. DOI: 10.1111/j.1423-0410.1975.tb02791.x. View

17.

Vermeulen M, van der Meche F, Speelman J, Weber A, BUSCH H . Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci. 1985; 70(3):317-26. DOI: 10.1016/0022-510x(85)90173-x. View

18.

van der Meche F, Schmitz P . A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992; 326(17):1123-9. DOI: 10.1056/NEJM199204233261705. View

19.

Kazatchkine M, Kaveri S . Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345(10):747-55. DOI: 10.1056/NEJMra993360. View

20.

Basta M, Van Goor F, Luccioli S, Billings E, Vortmeyer A, Baranyi L . F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med. 2003; 9(4):431-8. DOI: 10.1038/nm836. View